Unicycive Therapeutics Analyst Price Targets

Unicycive Therapeutics Inc

UNCYNASDAQ

Trade with Public

$3.51

0.154.46%

Últ. Act.: Oct 19, 6:56 PM

$3.63

0.278.04%

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

Unicycive Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Unicycive Therapeutics (UNCY).

Price Target Range — 11 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$38Upside to Avg. PT+943.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 29, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$15→$13
Aug 20, 2026	Benchmark	Bruce Jackson	PT Raise	Speculative Buy	$13→$15
Aug 13, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$37→$25
Aug 13, 2026	B. Riley Securities	Mayank Mamtani	PT Cut	Buy	$22→$20
Jul 1, 2026	Benchmark	Bruce Jackson	PT Cut	Speculative Buy	$18→$13
Jul 1, 2026	Noble Capital Markets	Robert LeBoyer	PT Cut	Outperform	$60→$50
Jun 30, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$22→$15
Jun 30, 2026	B. Riley Securities	Mayank Mamtani	Maintained	Buy	$22
Jun 2, 2026	Benchmark	Bruce Jackson	PT Raise	Speculative Buy	$15→$18
May 13, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$40→$37
Apr 6, 2026	Benchmark	Bruce D. Jackson	PT Cut	Speculative Buy	$21→$15
Apr 2, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$46→$40
Oct 29, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$9→$22
Sep 15, 2025	Benchmark	Bruce D. Jackson	PT Raise	Speculative Buy	$3→$21
May 27, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Assumes	Buy	$9
Apr 21, 2025	Guggenheim	Vamil Divan	Initiate	Buy	$6
Apr 11, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$8
Apr 1, 2025	HC Wainwright & Co.	Ed Arce	PT Raise	Buy	$4→$8
Jan 29, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$4
Jan 8, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$4

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $15 to $13.

Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15

Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and raises the price target from $13 to $15.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25

Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $37 to $25.

Benzinga Newsdesk

PRO
B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20

B. Riley Securities analyst Mayank Mamtani reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $22 to $20.

Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13

Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and lowers the price target from $18 to $13.

Benzinga Newsdesk

PRO
Noble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50

Noble Capital Markets analyst Robert LeBoyer maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Outperform and lowers the price target from $60 to $50.

Benzinga Newsdesk

Unicycive Therapeutics Inc

Unicycive Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13

PRO
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15

PRO
Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25

PRO
B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20

PRO
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13

PRO
Noble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Unicycive Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13

PRO
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15

PRO
Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25

PRO
B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20

PRO
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13

PRO
Noble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50

People Also Watch

People Also Watch

Unicycive Therapeutics Inc

Unicycive Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13

PROBenchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15

PROGuggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25

PROB. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20

PROBenchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13

PRONoble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Unicycive Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13

PROBenchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15

PROGuggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25

PROB. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20

PROBenchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13

PRONoble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13

PRO
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15

PRO
Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25

PRO
B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20

PRO
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13

PRO
Noble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50

PRO
HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13

PRO
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15

PRO
Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25

PRO
B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20

PRO
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13

PRO
Noble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50